Immuneering Corp. (IMRX) drew attention at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on Sept. 10, 2026, as it presented clinical data for atebimetinib, a deep cyclic inhibition MEK inhibitor targeting the MAPK pathway, in first-line pancreatic cancer.
In a Phase II study involving 55 patients, the combination of atebimetinib plus gemcitabine produced a median overall survival of 17.3 months, compared with an 8.5-month benchmark from the MPACT study of gemcitabine plus nab-paclitaxel. That represented a 104% improvement over the comparator regimen. Sixty percent of patients progressed to second-line therapy, versus 40% in the MPACT control arm.
Eighty-four percent of evaluable patients maintained or gained weight at three months, a marker that carries a hazard ratio of 1.55 relative to weight stability in published literature. Only two categories of treatment-related adverse events exceeded Grade 3 severity in more than 10% of patients.
Ben, Immuneering's co-founder and CEO, said the Deep Cyclic Inhibition approach aims to "block the pathway completely for several hours a day and then let go," giving the pathway back between dosing cycles. He added that "the ultimate survival that a patient is able to have is the sum of the benefit they get in first line, plus the probability that they can go on to second line, times the benefit that they get in second line."
Peter Vu, a physician at UC San Diego quoted by OncLive, said patients have shown remarkable quality-of-life improvements on the therapy.
The Phase III first-line pancreatic cancer trial began dosing its first patient in June 2024 across 43 sites listed on clinicaltrials.gov. Top-line results are expected in 2028.
A lung cancer study combining atebimetinib with anti-PD-1 therapy targeted first patient dosing by the end of 2024, with initial data expected by year-end 2025. An AACR poster presentation expanding on weight stability and survival implications is scheduled for late September.
Immuneering holds a U.S. composition-of-matter patent granted in summer 2024. Its lead competitor's RAS inhibitor, KRAZATI, was referenced during the session; only one of 55 Phase II patients received a RAS inhibitor in the second line, and removing that patient did not alter the median survival result.
At the time of the conference, IMRX shares were trading at $4.59, down 43% over the past year and 8.5% over the prior week. Market capitalization stood at $298 million, with a fair value estimate of $5.85 from InvestingPro. Levered free cash flow was negative $57 million over the last twelve months, while the current ratio exceeded 19. The MEK inhibitor market generated $3.7 billion in revenue in 2025, driven by MEK inhibitors alone or in combination with RAF inhibitors. Analyst price targets for IMRX ranged from $12 to $30.
